Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,104,931 articles, preprints and more)

Suggested authors matching "AUTH:Recher C" with an ORCID

Christian RECHER
CHU de TOULOUSE
4
Publications
826
Citations
View profile

Search results

1-25 of 341 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
Récher C, Dumas PY, Bérard E, Tavitian S, Leguay T, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Luquet I, Klein E, de Grande AC, Sarry A, Zukunft S, Platzbecker U, Müller-Tidow C, [...] Röllig C
Am J Hematol, 18 Nov 2024
Cited by: 0 articles | PMID: 39555737
Add to export list
The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.
DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C
Am J Hematol, 01 Nov 2024
Cited by: 0 articles | PMID: 39487568
Add to export list
Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.
Joudinaud R, Boudry A, Fenwarth L, Geffroy S, Salson M, Dombret H, Berthon C, Pigneux A, Lebon D, Peterlin P, Bouzy S, Flandrin-Gresta P, Tavernier E, Carre M, Tondeur S, Haddaoui L, Itzykson RA, Bertoli S, Bidet A, [...] Dumas PY
Blood Adv, bloodadvances.2024014672, 17 Oct 2024
Cited by: 0 articles | PMID: 39418643
Add to export list
Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS.
Cluzeau T, Guolo F, Chiche E, Minetto P, Rahmé R, Bertoli S, Fianchi L, Micol JB, Gottardi M, Peterlin P, Galimberti S, Thomas X, Rizzuto G, Legrand O, Rondoni M, Raffoux E, Bertani G, Caulier AL, Dargenio M, [...] Lemoli RM
Blood Adv, bloodadvances.2024014279, 25 Oct 2024
Cited by: 0 articles | PMID: 39454204
Add to export list
Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.
Lafarge A, Dupont T, Canet E, Moreau AS, Picard M, Mokart D, Platon L, Mayaux J, Wallet F, Issa N, Raphalen JH, Pène F, Renault A, Peffault de la Tour R, Récher C, Chevallier P, Zafrani L, Darmon M, Bigé N, Azoulay E
Am J Respir Crit Care Med, 210(8):1017-1024, 01 Oct 2024
Cited by: 0 articles | PMID: 39018219
Add to export list
Randomized Phase 2 Trial of Lirilumab as maintenance Treatment in Acute Myeloid Leukemia: Results of the EFFIKIR Trial
Vey N, Chretien A, Dumas P, Recher C, Gastaud L, Lioure B, Bulabois C, Pautas C, Marolleau J, Lepretre S, Raffoux E, Thomas X, Hichri Y, Bonmati C, Quesnel B, Rousselot P, Jourdan E, Malfuson J, Guillerm G, [...] Dombret H
medRxiv, 23 Aug 2024
Cited by: 0 articles | PPR: PPR900338
Add to export list Preprint
Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine.
Döhner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat V, Thirman MJ, Récher C, Schuh AC, Babu S, Li X, Ku G, Liu Z, Sun Y, Potluri J, Dail M, Chyla B, Pollyea DA
Blood, blood.2024024944, 12 Aug 2024
Cited by: 2 articles | PMID: 39133921
Add to export list
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.
Frontzek F, Renaud L, Dührsen U, Poeschel V, Bernard S, Chartier L, Ketterer N, Récher C, Fitoussi O, Held G, Casasnovas O, Haioun C, Mounier N, Tilly H, Morschhauser F, Le Gouill S, Karsten IE, Duns G, Steidl C, [...] Schmitz N
Leukemia, 38(10):2225-2234, 16 Aug 2024
Cited by: 0 articles | PMID: 39152324
Add to export list
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Harrison CN, Vannucchi AM, Recher C, Passamonti F, Gerds AT, Hernandez-Boluda JC, Yacoub A, Sirhan S, Ellis C, Patel B, Strouse B, Platzbecker U
Adv Ther, 41(9):3722-3735, 11 Jul 2024
Cited by: 1 article | PMID: 38990433 | PMCID: PMC11349857
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
Orvain C, Bertoli S, Peterlin P, Desbrosses Y, Dumas PY, Iat A, Hospital MA, Carre M, Tavernier E, Riou J, Bouvier A, Bidet A, Tondeur S, Renosi F, Mozziconacci MJ, Flandrin-Gresta P, Dadone-Montaudié B, Delabesse E, Pigneux A, [...] Recher C
Leukemia, 38(9):1949-1957, 17 Jul 2024
Cited by: 1 article | PMID: 39020060 | PMCID: PMC11347360
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia.
Le Floch AC, Orlanducci F, Béné MC, Ben Amara A, Rouviere MS, Salem N, Le Roy A, Cordier C, Demerlé C, Granjeaud S, Hamel JF, Ifrah N, Cornillet-Lefebvre P, Delaunay J, Récher C, Delabesse E, Pigneux A, Vey N, Chretien AS, Olive D
Blood Adv, 8(16):4262-4275, 01 Aug 2024
Cited by: 0 articles | PMID: 38788176 | PMCID: PMC11372596
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models.
Larrue C, Mouche S, Angelino P, Sajot M, Birsen R, Kosmider O, Mckee T, Vergez F, Recher C, Mas VM, Gu Q, Xu J, Tsantoulis P, Sarry JE, Tamburini J
Sci Transl Med, 16(757):eadk1731, 24 Jul 2024
Cited by: 0 articles | PMID: 39047119
Add to export list
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, [...] Récher C
Am J Hematol, 99(10):1870-1876, 20 Jun 2024
Cited by: 0 articles | PMID: 38899566
Add to export list
The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France.
Moulis G, Michel M, Bonnotte B, Godeau B, CARMEN-France investigators group, Collaborators (the CARMEN-France investigators group)
Rev Med Interne, 45(9):543-548, 02 Jul 2024
Cited by: 0 articles | PMID: 38960844
Add to export list Review
When acute promyelocytic leukaemia changes its face in the peripheral blood.
Le Grand S, Canali A, Bertoli S, Recher C, De Mas V, Rieu JB
EJHaem, 5(3):635-637, 24 May 2024
Cited by: 0 articles | PMID: 38895076 | PMCID: PMC11182383
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.
Récher C, Dumas P, Bérard E, Tavitian S, Leguay T, GALTIER J, Alric C, Bidet A, Delabesse E, Jean-Baptiste R, VIAL J, Vergez F, Luquet I, Klein E, De Grande A, Sarry A, Zukunft S, Platzbecker U, Müller-Tidow C, [...] Röllig C
Research Square, 10 Jun 2024
Cited by: 0 articles | PPR: PPR864956
Add to export list Preprint v1
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Gondran C, Dumas PY, Bérard E, Bidet A, Delabesse E, Tavitian S, Leguay T, Huguet F, Borel C, Forcade E, Vergez F, Vial JP, Rieu JB, Lechevalier N, Luquet I, Canali A, Klein E, Sarry A, de Grande AC, [...] Bertoli S
Blood Cancer J, 14(1):91, 31 May 2024
Cited by: 1 article | PMID: 38821940 | PMCID: PMC11143277
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Transplant in AML: just follow the NPM1 guide!
Récher C
Blood, 143(19):1881-1882, 01 May 2024
Cited by: 0 articles | PMID: 38722660
Add to export list
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Roboz GJ, Sanz G, Griffiths EA, Yee K, Kantarjian H, Récher C, Byrne MT, Patkowska E, Kim HJ, Thomas X, Moors I, Stock W, Illés Á, Fenaux P, Miyazaki Y, Yamauchi T, O'Connell CL, Hao Y, Keer HN, [...] Döhner H
Blood Adv, 8(8):2020-2029, 01 Apr 2024
Cited by: 1 article | PMID: 38231126 | PMCID: PMC11103175
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.
Récher C, Gondran C, Dumas P, BERARD E, Bidet A, DELABESSE E, Tavitian S, Leguay T, Huguet F, Borel C, Forcade E, Vergez F, VIAL J, [email protected] JB, LECHEVALIER N, LUQUET I, Canali A, KLEIN E, Sarry A, [...] Bertoli S
Research Square, 09 Apr 2024
Cited by: 0 articles | PPR: PPR834806
Add to export list Preprint v1
Differential prognostic values of the three AKT isoforms in acute myeloid leukemia.
Corre E, Soum C, Pfeifer R, Bessière C, Dailhau S, Marbœuf C, Meggetto F, Touriol C, Récher C, Bousquet M, Pyronnet S
Sci Rep, 14(1):7070, 25 Mar 2024
Cited by: 1 article | PMID: 38528080 | PMCID: PMC10963760
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.
Pratz KW, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Döhner H, Récher C, Fiedler W, Yamamoto K, Wang J, Yoon SS, Wolach O, Yeh SP, Leber B, Esteve J, Mayer J, Porkka K, Illés Á, Lemoli RM, [...] DiNardo CD
Am J Hematol, 99(4):615-624, 11 Feb 2024
Cited by: 9 articles | PMID: 38343151
Add to export list
Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.
Garciaz S, Berton G, Hospital MA, Guille A, Adélaïde J, Saillard C, Hicheri Y, Mozziconacci MJ, Duprez E, Récher C, Alary AS, Birnbaum D, Vey N
Leuk Lymphoma, 65(5):700-703, 08 Feb 2024
Cited by: 0 articles | PMID: 38329727
Add to export list
Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.
Didi I, Alliot JM, Dumas PY, Vergez F, Tavitian S, Largeaud L, Bidet A, Rieu JB, Luquet I, Lechevalier N, Delabesse E, Sarry A, De Grande AC, Bérard E, Pigneux A, Récher C, Simoncini D, Bertoli S
Leuk Res, 136:107437, 09 Jan 2024
Cited by: 0 articles | PMID: 38215555
Add to export list
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.
Leroy H, Gadaud N, Bérard E, Klein E, Luquet I, Vial JP, Rieu JB, Lechevalier N, Tavitian S, Leguay T, Largeaud L, Bidet A, Delabesse E, Sarry A, de Grande AC, Récher C, Pigneux A, Bertoli S, Dumas PY
Cancer Med, 13(3):e7003, 01 Feb 2024
Cited by: 1 article | PMID: 38400682 | PMCID: PMC10891460
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 341 results

1 2 3 Next ...

Search life-sciences literature (45,104,931 articles, preprints and more)

Suggested authors matching "AUTH:Recher C" with an ORCID

Search results

Mini-consolidations or intermediate-dose cytarabine for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia.

Long-term real world evidence of CPX-351 of high-risk AML patients identified high rate of negative MRD and prolonged OS.

Outcomes in Critically Ill Allogeneic Hematopoietic Stem-Cell Transplantation Recipients.

Randomized Phase 2 Trial of Lirilumab as maintenance Treatment in Acute Myeloid Leukemia: Results of the EFFIKIR Trial

Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine.

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials-a LYSA and GLA/ DSHNHL collaboration.

Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.

Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.

Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia.

Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models.

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

The CARMEN-France registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France.

When acute promyelocytic leukaemia changes its face in the peripheral blood.

Mini-consolidations or intermediate-dose cytarabine (IDAC) for the post-remission therapy of AML patients over 60. A retrospective study from the DATAML and SAL registries.

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

Transplant in AML: just follow the NPM1 guide!

Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.

Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

Differential prognostic values of the three AKT isoforms in acute myeloid leukemia.

Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.

Long-term survival of NPM1 AML treated with intensive chemotherapy with extensive molecular data available.

Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study.

Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.

Partnerships & funding

Search life-sciences literature (45,104,931 articles, preprints and more)

Suggested authors matching "AUTH:Recher C" with an ORCID Suggested authors have linked their articles in Europe PMC to their ORCID iD. Up to two suggested authors with a matching surname and initial are shown, ordered by the total number of publications they have in Europe PMC.

Search results

Partnerships & funding

Suggested authors matching "AUTH:Recher C" with an ORCID